PELO

Across TCGA pan-cancer cohorts, PELO mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PELO’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PELO mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PELO is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where PELO tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PELO mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.150	<.001	10	view →
LUAD	Male	All	+0.170	<.001	8	view →
HNSC	Male	II,III,IV	−0.136	<.001	6	view →
PDAC	All	III,IV	+0.333	.003	5	view →
LSCC	All	All	+0.140	<.001	5	view →
COAD	Male	All	−0.104	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PELO–CCRCC

Open the CCRCC breakdown →